Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy

Simple item page
dc.contributor.authorSarkar, Jen_US
dc.contributor.authorSaha, Den_US
dc.contributor.authorBandyopadhyay, Ben_US
dc.contributor.authorSaha, Ben_US
dc.contributor.authorChakravarty, Ren_US
dc.contributor.authorGuha, SKen_US
dc.date.accessioned2020-04-23T07:36:19Z
dc.date.available2020-04-23T07:36:19Z
dc.date.issued2018-06
dc.description.abstractBackground: Combination of tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV) is preferred in the treatment of HIV/hepatitis B virus (HBV) coinfection. We postulated that a HBV active nucleoside reverse transcriptase (RT) inhibitor/nucleotide RT inhibitor backbone of adefovir dipivoxil (ADV) +3TC would be as effective as TDF +3TC for the Indian population. Objective: ADV + 3TC could be an alternative option for these HIV/HBV coinfected individuals, preserving the dually active TDF + 3TC as second-line nucleoside backbone following failure of the first-line ART. Materials and Methods: This randomised control trial (CTRI/2012/03/002471) was carried out at the ART Centre of Calcutta School of Tropical Medicine, India. Seventy-eight (39 on each arm) treatment-naïve HIV/HBV coinfected patients were randomised to receive either the combination of lamivudine + tenofovir + EFV or lamivudine + adefovir + zidovudine + EFV and followed up for 120 weeks. Results: Median age of the study participants was 36 years (21–62), majority were male (61/78; 78.2%) and heterosexually (39/78; 50%) infected. Baseline characteristics were identical in both arms. There was no statistically significant difference in median aspartate aminotransferase (37 vs. 29.5 U/L), alanine aminotransferase (ALT) (36 vs. 34.5 U/L), ALT normalisation rate (80 vs. 70%), AST to platelet ratio index (0.45 vs. 0.33), CD4 count (508 vs. 427 cells/mm3), HBV DNA suppression (81.8 vs. 70%), hepatitis B e antigen loss (9 vs. 5%), hepatitis B surface antigen seroclearance rate (6.06 vs. 18.75%) and death (3 vs. 3) at 120 weeks between TDF (n = 33) and ADV (n = 32), respectively. Conclusions: Adefovir plus lamivudine is an effective alternative of tenofovir plus lamivudine in long-term HBV treatment outcome in HIV/HBV coinfected patients.en_US
dc.identifier.affiliationsDepartment of Tropical Medicine, Calcutta School of Tropical Medicine, Kolkata, West Bengal, Indiaen_US
dc.identifier.affiliationsDepartment of Virology ICMR Virus Unit, ID and BG Hospital Campus, Kolkata, West Bengal, Indiaen_US
dc.identifier.affiliationsDepartment of Microbiology, Calcutta School of Tropical Medicine, Kolkata, West Bengal, Indiaen_US
dc.identifier.citationSarkar J, Saha D, Bandyopadhyay B, Saha B, Chakravarty R, Guha SK. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy. Indian Journal of Medical Microbiology. 2018 Jun; 36(2): 217-223en_US
dc.identifier.issn0255-0857
dc.identifier.issn1998-3646
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/198757
dc.languageenen_US
dc.publisherIndian Association of Medical Microbiologistsen_US
dc.relation.issuenumber2en_US
dc.relation.volume36en_US
dc.source.urihttps://dx.doi.org/10.4103/ijmm.IJMM_17_37en_US
dc.subjectAdefoviren_US
dc.subjectanti-retroviral therapyen_US
dc.subjectHIV/hepatitis B virus coinfectionen_US
dc.subjectlamivudineen_US
dc.subjecttenofoviren_US
dc.titleLamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijmm2018v36n2p217.pdf
Size:
622.47 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Medical Microbiology